The findings of this study provide proof-of-concept for targeted inhibition of the immune checkpoint CD200, as samalizumab appears to have provided significant therapeutic benefit to some CLL patients despite a sub-optimal dosing schedule. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.